HekeTiss

HekeTiss SA is a spin-off from the University of Geneva and University Hospitals of Geneva (Switzerland) committed to the development of innovative therapies for patients affected by chronic ulcers. Chronic ulcers, which may manifest as a consequence of several diseases, including diabetes and cardiovascular disorders, affect more than 1% of the worldwide population. Living with a chronic ulcer is painful and disabling, leading to a significant impairment of the quality of life of patients and their family. HekeTiss is developing TrophiPatch, a cell-based skin patch that promotes superior cicatrization of skin wounds thanks to angiogenic and regenerative power of its cellular constituent: stem cells derived from the adipose tissue.